- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Cost-Utility Analysis of Once-Weekly Semaglutide Versus Dulaglutide in Patients With Type 2 Diabetes Requiring Treatment With a GLP-1 Receptor Agonist (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1816; Our results indicate that the introduction of once-weekly semaglutide as an alternative to dulaglutide is likely to be considered cost-effective for treatment intensification in patients insufficiently controlled on metformin plus sulfonylurea, at a commonly accepted threshold of 25 million KRW/QALY for non-severe diseases, and would lead to cost-savings and clinical benefits in those on basal insulin requiring treatment intensification.
- |||||||||| Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Cost-Effectiveness Analysis of Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes in China (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1695; Our results indicate that the introduction of once-weekly semaglutide as an alternative to dulaglutide is likely to be considered cost-effective for treatment intensification in patients insufficiently controlled on metformin plus sulfonylurea, at a commonly accepted threshold of 25 million KRW/QALY for non-severe diseases, and would lead to cost-savings and clinical benefits in those on basal insulin requiring treatment intensification. Compared with treatment with PEG-Loxenatide, once-weekly semaglutide represents a dominant option for treating patients with T2D in China who are not achieving glycemic control with metformin, projected to both improve clinical outcomes and reduce costs.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Observational data, Journal: Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. (Pubmed Central) - Aug 27, 2022 Compared with treatment with PEG-Loxenatide, once-weekly semaglutide represents a dominant option for treating patients with T2D in China who are not achieving glycemic control with metformin, projected to both improve clinical outcomes and reduce costs. The study documented benefits of semaglutide on metabolic control and multiple CV risk factors, simplification of therapeutic schemes and high satisfaction with diabetes treatment, and eating behaviors indicative of healthy diet and reduced food intake.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment open, Trial completion date, Trial primary completion date: Triple Therapy in T1DM (clinicaltrials.gov) - Aug 26, 2022 P2/3, N=114, Recruiting, Not yet recruiting --> Recruiting Unknown status --> Recruiting | Trial completion date: May 2022 --> Mar 2024 | Trial primary completion date: May 2022 --> Dec 2023
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Trial completion date, Trial primary completion date: Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - Aug 18, 2022 P2, N=81, Recruiting, Given this was a small-scale open-label trial, double-blind placebo-controlled trials with adequate patient numbers are warranted to assess the efficacy and safety of these combinations in NASH. Not yet recruiting --> Recruiting | Trial completion date: Jul 2024 --> Aug 2026 | Trial primary completion date: Jul 2023 --> Aug 2026
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Preclinical, Journal: Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. (Pubmed Central) - Aug 17, 2022 Not yet recruiting --> Recruiting | Trial completion date: Jul 2024 --> Aug 2026 | Trial primary completion date: Jul 2023 --> Aug 2026 These pre-clinical data suggest unimolecular poly-pharmacology as an effective means to target multiple mechanisms contributing to obesity and further implicate GcgR activation as the differentiating factor between incretin receptor mono- or dual-agonists and triagonists.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer? (Pubmed Central) - Aug 13, 2022 These results led to the approval of semaglutide by regulatory authorities as an adjunct to a reduced-calorie diet and increased physical activity in people with obesity or overweight, with at least one weight-related comorbidity. With data from phase II and III clinical trials showing that newer drugs (i.e. the glucagon-like peptide-1 and gastric inhibitory polypeptide dual receptor agonist tirzepatide and the amylin agonist cagrilintide, either alone or combined) produce a greater sustained weight loss than semaglutide, an upstream 'weight-centric' strategy has emerged as a new standard for the treatment of type 2 diabetes.
- |||||||||| Mounjaro (tirzepatide) / Eli Lilly
Review, Journal: Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. (Pubmed Central) - Aug 6, 2022 Tirzepatide was well tolerated, with a low risk of hypoglycaemia when used without insulin or insulin secretagogues and showed a generally similar safety profile to the GLP-1 receptor agonist class. Accordingly, evidence from these clinical trials suggests that tirzepatide offers a new opportunity for effective lowering of HbA1c and body weight in adults with type 2 diabetes.
- |||||||||| Journal: Cardiovascular effects of incretins - focus on GLP-1 receptor agonists. (Pubmed Central) - Aug 5, 2022
Liraglutide, oral semaglutide and exenatide once weekly also reduced mortality...In the 2019 consensus report from EASD/ADA, GLP-1 RAs with demonstrated cardio-renal benefits (liraglutide, semaglutide and dulaglutide) are recommended after metformin to patients with established cardiovascular diseases or multiple cardiovascular risk factors...However, the results from cardiovascular outcome trials (CVOT) are very heterogeneous suggesting that some GLP-1RA are more suitable to prevent CVD than others. The CVOTs provide a basis upon which individual treatment decisions for patients with T2D and CVD can be made.
|